INTRODUCTION: There are no controlled trials comparing etanercept and acitretin efficacy and therapeutic mechanisms in psoriasis. MATERIALS AND METHODS: In the present study, 30 patients were givenetanercept 50 mg twice weekly and 30 patients acitretin 0.4 mg/kg per day, both for 12 weeks. Before and after treatment, psoriasis area and severity index was calculated, and serum levels of interleukin (IL)-17, IL-22, and IL-23 were investigated. RESULTS: After treatment, psoriasis area and severity index was significantly lower for both groups. However, etanercept-treated patients showed lower psoriasis area and severity index than acitretin-treated ones. Psoriasis patients showed higher IL-17 and IL-22 levels than controls, while no IL-23 was found in any serum. Furthermore, a correlation between IL-17 levels and psoriasis severity was found. Only etanercept was able to reduce IL-17 and IL-22 levels. CONCLUSIONS: Our findings suggest that etanercept is more effective than acitretin in the treatment of psoriasis and that it is able to affect Th17 system.
RCT Entities:
INTRODUCTION: There are no controlled trials comparing etanercept and acitretin efficacy and therapeutic mechanisms in psoriasis. MATERIALS AND METHODS: In the present study, 30 patients were given etanercept 50 mg twice weekly and 30 patientsacitretin 0.4 mg/kg per day, both for 12 weeks. Before and after treatment, psoriasis area and severity index was calculated, and serum levels of interleukin (IL)-17, IL-22, and IL-23 were investigated. RESULTS: After treatment, psoriasis area and severity index was significantly lower for both groups. However, etanercept-treated patients showed lower psoriasis area and severity index than acitretin-treated ones. Psoriasispatients showed higher IL-17 and IL-22 levels than controls, while no IL-23 was found in any serum. Furthermore, a correlation between IL-17 levels and psoriasis severity was found. Only etanercept was able to reduce IL-17 and IL-22 levels. CONCLUSIONS: Our findings suggest that etanercept is more effective than acitretin in the treatment of psoriasis and that it is able to affect Th17 system.
Authors: J F Schlaak; M Buslau; W Jochum; E Hermann; M Girndt; H Gallati; K H Meyer zum Büschenfelde; B Fleischer Journal: J Invest Dermatol Date: 1994-02 Impact factor: 8.551
Authors: Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger Journal: J Exp Med Date: 2007-11-26 Impact factor: 14.307
Authors: A Chiricozzi; M Suárez-Fariñas; J Fuentes-Duculan; I Cueto; K Li; S Tian; C Brodmerkel; J G Krueger Journal: Br J Dermatol Date: 2015-11-11 Impact factor: 9.302
Authors: Andrew Johnston; Yi Fritz; Sean M Dawes; Doina Diaconu; Paul M Al-Attar; Andrew M Guzman; Cynthia S Chen; Wen Fu; Johann E Gudjonsson; Thomas S McCormick; Nicole L Ward Journal: J Immunol Date: 2013-01-28 Impact factor: 5.422
Authors: Mark Peric; Sarah Koglin; Yvonne Dombrowski; Katrin Gross; Eva Bradac; Amanda Büchau; Andreas Steinmeyer; Ulrich Zügel; Thomas Ruzicka; Jürgen Schauber Journal: PLoS One Date: 2009-07-22 Impact factor: 3.240